undamentalytics Newsletter
Sign in

Veracyte, Inc. balance sheet

At the end of fiscal 2025, Veracyte, Inc. had total assets of $1.41bn, total liabilities of $96.4m and shareholders' equity of $1.31bn. It held $363m in cash against $0 of debt: net cash of $363m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents814713539593478159349173154216239363300
Receivables—1134913131918414440474554
Inventory—1344353751114162221—
Total current assets—16764348745497188376243249286372488575
Goodwill———1111133708696703746767767
Total assets—19806575101791212754571,1881,1561,1151,3001,4061,486
Accounts payable—257524323121213958
Deferred revenue (current)—33210——00532211
Total current liabilities—91517151212131717646361796063
Short-term debt——————010010————
Long-term debt——555252524110—————
Total debt0055525252511100000
Total liabilities—1423232441414136369181711249698
Shareholders' equity−41−585641516037802394211,0971,0751,0441,1761,3101,388
Non-controlling interests and other (assets − liabilities − equity)—63——————————————
Net debt (negative = net cash)−8−14−66−30−34−34−9−53−159−349−172−154−216−239−363−300
Shares outstanding—3m21m23m28m34m34m41m50m58m71m72m73m78m79m80m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: AZTA vs VCYTTXG vs VCYTTWST vs VCYT

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Veracyte, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Veracyte, Inc.